Among patients with MCL still on study in January 2025, 35.3% reported improved MCL-related symptoms, while 5.9% reported ...

Margaret Krackeler, MD, discusses real-world data supporting the switch from ibrutinib to zanubrutinib for chronic lymphocytic leukemia.

Adults with nonmelanoma skin cancer reported higher unadjusted levels of day-to-day mental distress, but adjusted analyses showed no significant association with depression and a slight decrease in ...

Ariana Levin, MD, assistant professor in the Department of Ophthalmology at NYU Grossman School of Medicine, discussed how open communication between the ophthalmologist or optometrist and their ...

Dermatology is entering a "biological revolution," with engineered tissues and bio-machines offering new therapeutic ...

The HELIOS-B trial previously showed that vutrisiran (Amvuttra; Alnylam Pharmaceuticals), a gene-silencing therapy that ...

An article published in TechTarget referenced a study published in the January 2026 issue of The American Journal of Managed ...

ASH 2025 immunotherapy data highlight the importance of treatment sequencing, real-world outcomes in high-risk populations, ...

Data at ASH 2025 highlighted that standardized workflows, education, monitoring innovations, and collaboration are steadily ...

Manjool Shah, MD, clinical associate professor of ophthalmology and visual sciences for the Kellogg Eye Center, discussed how ...

Adopting zanubrutinib for the treatment of chronic lymphocytic leukemia showed improved tolerability and persistence, ...

Adults with allergic rhinitis experience diagnostic delays and limited access to allergen immunotherapy, impacting quality of life and treatment satisfaction. ICE activity in Minnesota healthcare ...